Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 76.09

+4.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jopawa who wrote (2030)	6/10/1998 2:44:00 PM
From: Peter Singleton	Read Replies (1) of 4676

Folks, this was the publishing of the pilot PII Crohn's results in a peer-reviewed journal. This was the data that was released in a press release I think over a year ago, and has been presented at a couple of conferences. That said, it is very important data about the potential for 2302, and validation of antisense in systemic administration (and for a 1st gen molecule), and publication in a peer-reviewed journal will find a larger audience, but of course, it's not new news. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next